Study of HRS-1893 for non-obstructive hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new medicine called HRS-1893 for people with a type of thick heart muscle disease that does not block blood flow. The goal is to see if it can improve symptoms or slow the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- Your body mass index (BMI) is less than 35.
- You have non-obstructive hypertrophic cardiomyopathy.
- You have not had fainting or dangerous fast heart rhythms in the past 6 months.
- You are not currently in atrial flutter or atrial fibrillation with symptoms.
- If you could become pregnant or get someone pregnant, you must use reliable birth control during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
This is an early-stage safety test of a new experimental drug called HRS-5765 in people without serious health conditions. Researchers want to make sure the drug is safe and understand how your body processes it.
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
This study tests whether a new drug called HRS9531 can help people with atherosclerotic cardiovascular disease (hardened arteries affecting the heart and blood vessels). The trial will check if it's safe and effective for managing this condition.
Hear when a new Non-obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.